Drug Profile
Busulfan intravenous - Otsuka Pharmaceutical
Alternative Names: Busilvex; Busulfan - Orphan Medical; Busulfex; IV busulfan - Otsuka; KRN 246Latest Information Update: 30 Dec 2021
Price :
$50
*
At a glance
- Originator Orphan Medical; PDL BioPharma
- Developer Kirin Holdings Company; Knight Therapeutics; Orphan Medical; Otsuka Pharmaceutical; Tzamal Pharma
- Class Antineoplastics; Butylene glycols; Glycols; Mesylates; Myeloablative agonists; Small molecules
- Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ewing's sarcoma; Haematological malignancies; Lymphoma; Neuroblastoma
- Phase II Multiple myeloma; T-cell lymphoma